/ /

  • linkedin
  • Increase Font
  • Sharebar

    Drug-delivery technologies will transform care

     

    A single fiber injected into the conjunctiva delivers a steady dose of latanoprost.  The drug-eluting fiber showed a 6 mm Hg reduction in IOP over 6 months, she said. The IOP reduction is similar to eye drops with fewer adverse events compared to topical drops and full adherence.

    “The ophthalmologist can take direct control of treatment and address the poor adherence that is typical with eye drops,” Gillissen said. “The patient is relieved of the need for daily drug and the reduction in quality of life due to glaucoma advancing when they are not adherent. For the pharma industry, the drug-laden fiber offers a new delivery product in a competitive market.”

    Envisia Therapeutics

    Envisia Therapeutics borrowed from microelectronics to print micro- and nano-sized polymers that can be filled with active ingredient and injected or inserted into the appropriate ocular site. The company is in phase IIa on a 6-month biodegradable rod-shaped formulation of travoprost for glaucoma, said Chief Scientific Officer Benjamin Yerxa, PhD. Future plans include an IND for biodegradable steroid formulations for post cataract inflammation and extended release formulations of biologic agents.

    In a beagle model, an intracameral travoprost implant showed a 32% reduction in IOP from baseline over 8 months from a single dose. Yerxa said he hoped to have human data to report in 2016.

    “The drug is available 24/7 at the optimal concentration,” Yerxa said. “The rod is fully biodegradable and nothing is left in the eye at 6 months. This puts treatment in the hands of the clinician, not the patient.”

    ForSight VISION5

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results